Sloan JA - Search Results

1

Sample size and design considerations for phase II clinical trials with correlated observations.

Sargent DJ, Sloan JA, Cha SS. Sargent DJ, et al. Among authors: sloan ja. Control Clin Trials. 1999 Jun;20(3):242-52. doi: 10.1016/s0197-2456(98)00058-0. Control Clin Trials. 1999. PMID: 10357497

2

Incremental costs of enrolling cancer patients in clinical trials: a population-based study.

Wagner JL, Alberts SR, Sloan JA, Cha S, Killian J, O'Connell MJ, Van Grevenhof P, Lindman J, Chute CG. Wagner JL, et al. Among authors: sloan ja. J Natl Cancer Inst. 1999 May 19;91(10):847-53. doi: 10.1093/jnci/91.10.847. J Natl Cancer Inst. 1999. PMID: 10340904

3

Design considerations for efficient prostate cancer chemoprevention trials.

Lee JJ, Lieberman R, Sloan JA, Piantadosi S, Lippman SM. Lee JJ, et al. Among authors: sloan ja. Urology. 2001 Apr;57(4 Suppl 1):205-12. doi: 10.1016/s0090-4295(00)00976-6. Urology. 2001. PMID: 11295629

4

Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials.

Sloan JA, Dueck A. Sloan JA, et al. J Biopharm Stat. 2004 Feb;14(1):73-96. doi: 10.1081/BIP-120028507. J Biopharm Stat. 2004. PMID: 15027501

5

Overall survival and self-reported fatigue in patients with esophageal cancer.

Stauder MC, Romero Y, Kabat B, Atherton PJ, Geno D, Deschamps C, Jatoi A, Sloan JA, Botros M, Jung KW, Arora AS, Miller RC; EABE Registry Consortium. Stauder MC, et al. Among authors: sloan ja. Support Care Cancer. 2013 Feb;21(2):511-9. doi: 10.1007/s00520-012-1537-1. Epub 2012 Jul 29. Support Care Cancer. 2013. PMID: 22842921

6

Quality of Life endpoints in prostate chemoprevention trials.

Sloan JA, Varricchio C. Sloan JA, et al. Urology. 2001 Apr;57(4 Suppl 1):235-40. doi: 10.1016/s0090-4295(00)00982-1. Urology. 2001. PMID: 11295635

7

A simple stratification factor prognostic for survival in advanced cancer: the good/bad/uncertain index.

Sloan JA, Loprinzi CL, Laurine JA, Novotny PJ, Vargas-Chanes D, Krook JE, O'Connell MJ, Kugler JW, Tirona MT, Kardinal CG, Wiesenfeld M, Tschetter LK, Hatfield AK, Schaefer PL. Sloan JA, et al. J Clin Oncol. 2001 Aug 1;19(15):3539-46. doi: 10.1200/JCO.2001.19.15.3539. J Clin Oncol. 2001. PMID: 11481361

8

Methodologic lessons learned from hot flash studies.

Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Sloan JA, et al. J Clin Oncol. 2001 Dec 1;19(23):4280-90. doi: 10.1200/JCO.2001.19.23.4280. J Clin Oncol. 2001. PMID: 11731510

9

Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer.

Sloan JA, Loprinzi CL, Kuross SA, Miser AW, O'Fallon JR, Mahoney MR, Heid IM, Bretscher ME, Vaught NL. Sloan JA, et al. J Clin Oncol. 1998 Nov;16(11):3662-73. doi: 10.1200/JCO.1998.16.11.3662. J Clin Oncol. 1998. PMID: 9817289 Clinical Trial.

10

Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.

Pitot HC, McElroy EA Jr, Reid JM, Windebank AJ, Sloan JA, Erlichman C, Bagniewski PG, Walker DL, Rubin J, Goldberg RM, Adjei AA, Ames MM. Pitot HC, et al. Among authors: sloan ja. Clin Cancer Res. 1999 Mar;5(3):525-31. Clin Cancer Res. 1999. PMID: 10100703 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

447 results

Search Page